CN102770016A - 来源于转基因植物的高致病性禽流感病毒蛋白疫苗及其制备方法 - Google Patents

来源于转基因植物的高致病性禽流感病毒蛋白疫苗及其制备方法 Download PDF

Info

Publication number
CN102770016A
CN102770016A CN2010800563463A CN201080056346A CN102770016A CN 102770016 A CN102770016 A CN 102770016A CN 2010800563463 A CN2010800563463 A CN 2010800563463A CN 201080056346 A CN201080056346 A CN 201080056346A CN 102770016 A CN102770016 A CN 102770016A
Authority
CN
China
Prior art keywords
protein
hemagglutinin
virus
present
plant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800563463A
Other languages
English (en)
Chinese (zh)
Inventor
黃仁焕
孙恩珠
权恩惠
罗允贞
全恩贤
任世镇
朴基硕
成永喆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helix Co Ltd Korea
Original Assignee
Helix Co Ltd Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Co Ltd Korea filed Critical Helix Co Ltd Korea
Publication of CN102770016A publication Critical patent/CN102770016A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2010800563463A 2009-10-06 2010-10-06 来源于转基因植物的高致病性禽流感病毒蛋白疫苗及其制备方法 Pending CN102770016A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20090094627 2009-10-06
KR10-2009-0094627 2009-10-06
KR1020100096488A KR101262300B1 (ko) 2009-10-06 2010-10-04 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법
KR10-2010-0096488 2010-10-04
PCT/KR2010/006821 WO2011043584A2 (ko) 2009-10-06 2010-10-06 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법

Publications (1)

Publication Number Publication Date
CN102770016A true CN102770016A (zh) 2012-11-07

Family

ID=44045255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800563463A Pending CN102770016A (zh) 2009-10-06 2010-10-06 来源于转基因植物的高致病性禽流感病毒蛋白疫苗及其制备方法

Country Status (6)

Country Link
US (1) US20120219580A1 (enExample)
EP (1) EP2486791A4 (enExample)
KR (1) KR101262300B1 (enExample)
CN (1) CN102770016A (enExample)
IN (1) IN2012DN03330A (enExample)
WO (1) WO2011043584A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018227698A1 (zh) * 2017-06-16 2018-12-20 王跃驹 植物作为宿主在表达中东呼吸综合征的疫苗中的应用
CN109563518A (zh) * 2016-05-12 2019-04-02 巴伊沃爱普有限公司 来自植物的用于经典猪瘟的疫苗组合物及其制造方法
CN109563138A (zh) * 2016-06-03 2019-04-02 圣诺菲·帕斯图尔公司 经改造的流感血凝素多肽的修饰
CN113692445A (zh) * 2019-04-02 2021-11-23 巴伊沃爱普有限公司 优化植物中表达的重组鸢尾素基因及使用其生产重组鸢尾素蛋白的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101535704B1 (ko) * 2012-12-28 2015-07-27 한국생명공학연구원 항원성 단백질 고정화를 통한 돈단독 백신 제조방법
US9624272B2 (en) 2013-03-14 2017-04-18 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
KR101602562B1 (ko) * 2014-06-10 2016-03-10 포항공과대학교 산학협력단 인플루엔자 a 바이러스 h5n1의 헤마글루티닌을 발현하는 식물체 및 사포닌을 포함하는 경구용 인플루엔자 a 바이러스 h5n1 백신 조성물
KR102128453B1 (ko) * 2018-03-23 2020-07-01 주식회사 젠바디 황열 바이러스 유래 ns1 단백질, 이에 특이적으로 결합하는 단일클론항체 및 이의 용도
KR102138272B1 (ko) * 2018-09-19 2020-07-28 주식회사 바이오앱 BiP 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
KR102317403B1 (ko) * 2019-01-28 2021-10-29 주식회사 바이오앱 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054540A2 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN101284130A (zh) * 2007-04-09 2008-10-15 生宝生物科技股份有限公司 利用逆向基因工程技术开发蛋白质疫苗与禽流感疫苗的方法
EP1997831A1 (en) * 2006-02-28 2008-12-03 Centro De Ingenieria Genetica Y Biotecnologia Chimeric vaccine antigens against the avian influenza virus
US20090124567A1 (en) * 2002-09-28 2009-05-14 Jianzhu Chen Influenza Therapeutic

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100769584B1 (ko) 2004-07-30 2007-10-23 학교법인 포항공과대학교 셀룰로오스의 자가가수분해를 위한 셀룰라아제 발현형질전환 식물체 및 이를 이용한 수용성 당의 생산방법
CN1884517B (zh) * 2006-06-08 2010-06-30 武汉禾元生物科技有限公司 利用谷物非储藏蛋白为融合载体在胚乳表达多肽的方法及应用
US8158264B2 (en) 2006-10-20 2012-04-17 3M Innovative Properties Company Method for easy-to-clean substrates and articles therefrom
KR101161622B1 (ko) * 2009-08-31 2012-07-04 헬릭스 주식회사 번역 효율 증진용 ｄｎａ 단편 및 이를 포함하는 재조합 벡터

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124567A1 (en) * 2002-09-28 2009-05-14 Jianzhu Chen Influenza Therapeutic
EP1997831A1 (en) * 2006-02-28 2008-12-03 Centro De Ingenieria Genetica Y Biotecnologia Chimeric vaccine antigens against the avian influenza virus
WO2008054540A2 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN101284130A (zh) * 2007-04-09 2008-10-15 生宝生物科技股份有限公司 利用逆向基因工程技术开发蛋白质疫苗与禽流感疫苗的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN P.WANAMAKER ET AL.: "Endoplasmic Reticulum Chaperones Stabilize Nicotinic Recept or Subunits and Regulate Receptor Assembly", 《 THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
HIROSHI KURODA ET AL.: "Sequences Downstream of the Translation Initiation Codon Are Important Determinants of Translation Efficiency in Chloroplasts1", 《PLANT PHYSIOLOGY》 *
YOKO SHOJI ET AL.: "Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants", 《VACCINE》 *
YOKO SHOJI ET AL.: "Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants", 《VACCINE》, vol. 27, 5 February 2009 (2009-02-05), pages 3467 - 3470, XP026122484, DOI: doi:10.1016/j.vaccine.2009.01.051 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563518A (zh) * 2016-05-12 2019-04-02 巴伊沃爱普有限公司 来自植物的用于经典猪瘟的疫苗组合物及其制造方法
CN109563138A (zh) * 2016-06-03 2019-04-02 圣诺菲·帕斯图尔公司 经改造的流感血凝素多肽的修饰
US11904012B2 (en) 2016-06-03 2024-02-20 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides
WO2018227698A1 (zh) * 2017-06-16 2018-12-20 王跃驹 植物作为宿主在表达中东呼吸综合征的疫苗中的应用
CN113692445A (zh) * 2019-04-02 2021-11-23 巴伊沃爱普有限公司 优化植物中表达的重组鸢尾素基因及使用其生产重组鸢尾素蛋白的方法

Also Published As

Publication number Publication date
KR20110037880A (ko) 2011-04-13
EP2486791A2 (en) 2012-08-15
EP2486791A4 (en) 2013-06-12
KR101262300B1 (ko) 2013-05-20
WO2011043584A3 (ko) 2011-10-20
US20120219580A1 (en) 2012-08-30
WO2011043584A9 (ko) 2011-09-01
WO2011043584A2 (ko) 2011-04-14
IN2012DN03330A (enExample) 2015-10-23

Similar Documents

Publication Publication Date Title
CN102770016A (zh) 来源于转基因植物的高致病性禽流感病毒蛋白疫苗及其制备方法
Yusibov et al. Plant viral vectors based on tobamoviruses
CN102695524B (zh) 包含与植物病毒衣壳蛋白融合的靶蛋白的病毒样颗粒
US7901691B2 (en) Chimeric G protein based rabies vaccine
EA018206B1 (ru) Вирусоподобные частицы вируса гриппа, включающие гемагглютинин, продуцированный в растении
JP2005537796A (ja) 変性剤安定および／またはプロテアーゼ耐性シャペロン様オリゴマータンパク質、これらをコードするポリヌクレオチド、これらの使用、およびこれらの比活性を増加させる方法
BRPI0707733A2 (pt) antÍgenos de gripe, composiÇÕes de vacina, e mÉtodos relacionados
US6979448B1 (en) Chimaeric plant viruses with mucin peptides
Shahid et al. Early stage development of a Newcastle disease vaccine candidate in corn
JP5008811B2 (ja) ライノウイルス感染を防止するための免疫接着物
KR102053009B1 (ko) 돼지 열병 백신용 조성물 및 이의 제조 방법
US12357686B2 (en) Porcine epidemic diarrhea (PED) virus vaccine composition and preparation method thereof
US8557246B2 (en) Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof
US10857217B2 (en) Antigen fused with porcine Fc fragment and vaccine composition comprising the same
US20170239345A1 (en) Methods and compositions to produce vaccines against smallpox in plants
US20220088167A1 (en) Vaccine composition for preventing tuberculosis, comprising glycosylated ag85a protein and method for preparing same
KR101602562B1 (ko) 인플루엔자 a 바이러스 h5n1의 헤마글루티닌을 발현하는 식물체 및 사포닌을 포함하는 경구용 인플루엔자 a 바이러스 h5n1 백신 조성물
JP7640956B2 (ja) 三量体を形成する新型コロナウイルス（ｃｏｖｉｄ－１９、コロナウイルス感染症２０１９）の組換えスパイクタンパク質および植物における上記組換えスパイクタンパク質の大量生産方法と、これを基盤とするワクチン組成物の製造方法（植物における新型コロナウイルスの三量体スパイクタンパク質の生産方法およびワクチン接種のための使用）
CN111565747B (zh) 与猪fc片段融合的抗原，以及包含该抗原的疫苗组合物
EP2576602B1 (en) Chimeric momp antigen, method and use
KR20120066555A (ko) 돼지 유행성 설사병 바이러스의 에피토프 단백질을 발현하는 형질전환체 및 이를 포함하는 ｐｅｄｖ 백신 조성물
KR20230105738A (ko) 당쇄 구조가 변형된 식물로부터 생산된 SARS-CoV-2의 스파이크 단백질의 수용체 결합 도메인 및 이의 용도
KR20240120818A (ko) 식물 발현 재조합 지카바이러스 외피단백질을 포함하는 백신 조성물 및 이의 제조방법
Yusibov et al. Plant viral expression vectors: history and new developments
Bailey Expression in plants and immunogenicity of a fusion protein containing an epitope from the swine transmissible gastroenteritis virus S protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121107